Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer

NCT02793219 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Dendreon was sold and new company decided not to fund study.

Conditions

Prostate Cancer

Interventions

BIOLOGICAL: Sipuleucel-T
DRUG: Docetaxel

Sponsor

The University of Texas Health Science Center, Houston